Versor Investments LP Arvinas, Inc. Transaction History

Versor Investments LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 30, 2023	SELL	$32.47 - $57.24 $1.23 Million - $2.17 Million	-37,876 Reduced 60.93%	24,286 $830,000
Q3 2022 Oct 25, 2022	SELL	$41.87 - $57.99 $435,866 - $603,675	-10,410 Reduced 14.34%	62,162 $2.77 Million
Q2 2022 Jul 27, 2022	BUY	$36.01 - $74.24 $1.82 Million - $3.76 Million	50,651 Added 231.06%	72,572 $3.06 Million
Q1 2022 May 04, 2022	BUY	$60.27 - $81.57 $1.07 Million - $1.45 Million	17,721 Added 421.93%	21,921 $1.48 Million
Q4 2021 Feb 08, 2022	BUY	$65.85 - $96.21 $276,570 - $404,082	4,200 New	4,200 $345,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Versor Investments LP, based on Form 13F filings with the SEC.

Stay updated on Versor Investments LP with notifications on news.